This open-label, single-arm study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in patients with active moderate to severe rheumatoid arthritis. Patients will receive a subcutaneous dose of RoActemra/Actemra 162 mg once weekly. The anticipated time on study treatment is 24 weeks.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01951170?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
